Foundation Sponsors National Lymphoma Awareness Week

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

LOS ANGELES-The Lymphoma Research Foundation of America launched its second annual National Lymphoma Awareness Week on October 12. Actress Kelly Lynch, whose sister Robyn Lynch is a lymphoma survivor, served as honorary chair of the week, which featured a slate of events to inform the public about this cancer.

LOS ANGELES—The Lymphoma Research Foundation of America launched its second annual National Lymphoma Awareness Week on October 12. Actress Kelly Lynch, whose sister Robyn Lynch is a lymphoma survivor, served as honorary chair of the week, which featured a slate of events to inform the public about this cancer.

Robin and Kelly Lynch spoke at the educational forum organized by the Foundation last year in Los Angeles regarding their personal experiences. Robyn was diagnosed with Hodgkin’s disease in July 1995. Kelly has stood by her sister’s side through her lymphoma treatment and recovery. This winter, the actress will be seen in the film Homegrown with Billy Bob Thorton and will star in Disney’s feature film Mr. Magoo.

On October 18, an all-day educational forum for lymphoma patients, their families, and health care providers was held in Vienna, Virginia. Awareness Week concluded with the presentation of the first Paul Tsongas Memorial Awards (see People & Places on page 53).

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content